NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology GrowthOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 11.1% ye...
NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On RevenueOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 11.1% yea...
NeoGenomics Earnings: What To Look For From NEOOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) will be reporting results this Tuesday after market close. Here’s what investors should know. ...
Why NeoGenomics (NEO) Stock Is Trading Up TodayWhat Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) jumped 4.1% in the afternoon session after the company announced that...
2 Healthcare Stocks Worth Your Attention and 1 We IgnoreHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl...
3 Unprofitable Stocks Walking a Fine LineRunning at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding...
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The PackLet’s dig into the relative performance of NeoGenomics (
NASDAQ:NEO) and its peers as we unravel the now-completed Q4 testing & diagnostics services earnings ...
3 Cash-Burning Stocks We Think Twice AboutWhile some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...
3 of Wall Street’s Favorite Stocks We Think Twice AboutWall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To KnowWhat Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...
3 Reasons to Avoid NEO and 1 Stock to Buy InsteadWhat a fantastic six months it’s been for NeoGenomics. Shares of the company have skyrocketed 48.3%, hitting $9.94. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings CallNeoGenomics’ fourth quarter results were met with a negative market reaction, despite revenue and non-GAAP earnings per share surpassing Wall Street’s expectations. Management attributed the quarter’s performance to continued growth in next-generation sequencing (NGS) test volumes, robust adoption of new products, and a deliberate shift away from lower-value, high-volume testing. CEO Anthony Zook noted, “Our clinical business continued its robust growth with revenue increasing 16% year over year,” highlighting the company’s ability to drive higher average revenue per test through targeted commercial execution.
Why NeoGenomics (NEO) Shares Are Falling TodayShares of oncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO)
fell 10.1% in the afternoon session after the company reported fourth-quarter results that beat expectations but issued a full-year 2026 forecast that fell short of analyst predictions.
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on OutlookOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company expects the full year’s revenue to be around $797 million, close to analysts’ estimates. Its non-GAAP profit of $0.06 per share was $0.02 above analysts’ consensus estimates.
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat EstimatesOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company expects the full year’s revenue to be around $797 million, close to analysts’ estimates. Its non-GAAP profit of $0.06 per share was $0.02 above analysts’ consensus estimates.
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look ForOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO)
will be announcing earnings results this Tuesday before the bell. Here’s what investors should know.
